Komori
StemCell Institute (7096) · FactAdvanced

Cost Increases Driven by Increased Staffing, Wage Revisions, Higher Raw Material Prices, and Upfront Investment in Overseas Operations

First written in FY2026-H1. 3 of 5 entries say "Advanced", first in 2026-05-13. Latest entry: FY2026.

5entries
2years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2026-H1Advanced2026-05-13 – FY20262025: 120252026: 42026
Same theme, other companies
Multifaceted Growth-Related Cost Increases and Pressure on ProfitA theme 38 companies write about · 38 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2020: 6 of 21 companies on the "Worse" side.

1 other company's latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 38 companies compared. The sentences above are computed from all 38.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Selling, general and administrative expenses for the consolidated fiscal year amounted to ¥1,509.529 million. Selling, general and administrative expenses also increased due to the impact of business launch costs at the Singapore subsidiary, which is currently the Company's primary focus.」

    Expenses increased due to costs associated with launching the Singapore business, increased staffing and wage revisions, and higher raw material prices, resulting in an operating profit margin of 7.2%. The Company described these costs as upfront investment for market development.
  2. FY2026-H1First statedAnnual report

    「Cost of sales increased due to higher personnel expenses resulting from increased staffing and wage revisions made in anticipation of future business expansion, as well as rising raw material prices. Selling, general and administrative expenses were also affected by upfront investment related to launching the Singapore business, higher advertising expenses and, similarly, rising personnel expenses. These represent upfront investments in anticipation of future business expansion, and profit margins are expected to improve as earnings scale increases.」

    Increased staffing and wage revisions, higher raw material prices, investment in launching the Singapore business and advertising expenses were presented together for the first time as factors driving the increase in expenses. The Company described these as upfront investments for future business expansion and expects profit margins to improve as earnings scale increases.
Moved together

"Recruitment and Development of Specialist Talent and Digitalization of Operations" moved the same way as this thread, in the same document, in 2 of its 5 moves.

222222★123456
  1. ★This thread
  2. 1Recruitment and Development of Specialist Talent and Digitalization of Operations2×
  3. 2Support for Clinical Research in Regenerative Medicine and Cell Therapy Using Umbilical Cord Blood2×
  4. 3Technology Development Through Joint Research with Universities and Research Institutions2×
  5. 4Overseas business expansion focused on Asia2×
  6. 5Expansion of Cell Processing and Storage Capacity2×
  7. 6New Business Development Using Menstrual Blood-Derived Stem Cells and Culture-Derived Products2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for StemCell Institute yet. It last moved in the Revisions to earnings forecasts of 2026-05-13: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.